Abstract
Lopinavir/ritonavir is the first and only coformulated HIV-1 protease inhibitor (PI). Large clinical trials have demonstrated lopinavir/ ritonavir's clinical efficacy in both antiretroviral-naïve and -experienced patients. The immunologic and virologic benefits of treatment with this agent have been proven in HIV-infected adults, adolescents, and children. Smaller studies support the use of lopinavir/ ritonavir monotherapy as a therapeutic option in certain patients. The drug is characterized by a high genetic barrier to resistance, and appears to be more forgiving of non-adherence than earlier, unboosted PIs. The most frequent side effects observed are diarrhea, nausea, and vomiting. These gastrointestinal adverse effects are generally mild to moderate. Metabolic derangements, including hyperlipidemia and glucose intolerance, have also been observed in lopinavir/ritonavir recipients. As the menu of available antiretroviral agents continues to expand, lopinavir/ritonavir remains a proven and effective drug for the treatment of HIV infection.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1023-1033 |
| Number of pages | 11 |
| Journal | Therapeutics and Clinical Risk Management |
| Volume | 4 |
| Issue number | 5 |
| State | Published - 2008 |
Keywords
- Antiretroviral
- HIV
- Kaletra®
- Lopinavir/ritonavir
- Protease inhibitor
ASJC Scopus subject areas
- General Pharmacology, Toxicology and Pharmaceutics
- Pharmacology (medical)
- Chemical Health and Safety
- Safety Research
